問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Dermatology

National Taiwan University Hospital Hsin-Chu Branch

Division of Dermatology

更新時間：2026-03-22

蔡呈芳TSAI, TSEN-FANG
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 7 個月

Recruiting Trial

34Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡呈芳

List

65Cases

2017-07-01 - 2022-01-01

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study Followed by Long-Term Treatment for Evaluation of Efficacy and Safety of Baricitinib in Patients with Active Psoriatic Arthritis

  • Condition/Disease

    Psoriatic Arthritis

  • Test Drug

    Baricitinib (LY3009104)

Participate Sites
9Sites

Not yet recruiting8Sites

2018-03-01 - 2021-06-30

Phase III

A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis

  • Condition/Disease

    Atopic Dermatitis

  • Test Drug

    Baricitinib (LY3009104)

Participate Sites
6Sites

Terminated6Sites

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2017-11-01 - 2019-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

  • Condition/Disease

    Moderate to Severe Atopic Dermatitis

  • Test Drug

    Baricitinib (LY3009104)

Participate Sites
6Sites

Terminated6Sites

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2015-08-01 - 2017-12-31

Phase III

A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis

  • Condition/Disease

    Moderate-to-Severe Plaque Psoriasis

  • Test Drug

    Ixekizumab

Participate Sites
4Sites

Terminated4Sites

2019-05-01 - 2021-08-26

Phase II/III

A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GREATER SCALP HAIR LOSS

  • Condition/Disease

    Alopecia Areata (AA)

  • Test Drug

    PF-06651600

Participate Sites
6Sites

Recruiting6Sites

2014-03-01 - 2016-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2011-07-01 - 2013-06-30

Phase III

A randomized, double-blind, placebo controlled,multicenter study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tolerability and long-term efficacy up to one year in subjects with moderate to severe chronic plaque-type psoriasis

  • Condition/Disease

    moderate to severe chronic plaque-type psoriasis

  • Test Drug

    Secukinumab (AIN457)

Participate Sites
3Sites

Terminated3Sites

2012-07-01 - 2015-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2019-08-01 - 2021-12-31

Phase III

BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

  • Condition/Disease

    Masseter Muscle Prominence

  • Test Drug

    BOTOX®

Participate Sites
4Sites

Terminated4Sites

2014-05-31 - 2017-12-31

Phase II

BOTOX® Treatment of Masseter Muscle Hypertrophy

  • Condition/Disease

    BOTOX® Treatment of Masseter Muscle Hypertrophy

  • Test Drug

    BOTOX

Participate Sites
4Sites

Terminated4Sites

1 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB